TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Brief Summary: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.


Options:
A: Arm Label: Arm A: trabectedin + DOXIL; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin, Drug: DOXIL, Drug: Dexamethasone | Arm Label: Arm B: DOXIL; Type: ACTIVE_COMPARATOR; Interventions: Drug: DOXIL | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Arm A: trabectedin + DOXIL | Intervention Type: DRUG; Name: DOXIL; Assigned to Arm(s): Arm B: DOXIL
B: Arm Label: carboplatin and doxorubicin; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: pegylated liposomal doxorubicin hydrochloride | Arm Label: carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): carboplatin, carboplatin and doxorubicin | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): carboplatin and doxorubicin
C: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment
Brief Summary: Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.


Options:
A: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD
B: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy
D: Arm Label: Cyclophosphamide and BIBF-1120; Type: EXPERIMENTAL; Interventions: Drug: BIBF 1120 | Arm Label: Cyclophosphamide and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIBF 1120 | Intervention Type: DRUG; Name: BIBF 1120; Assigned to Arm(s): Cyclophosphamide and BIBF-1120, Cyclophosphamide and placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.


Options:
A: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
B: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
C: Arm Label: CVVH arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the CVVH method | Arm Label: IHD arm; Type: ACTIVE_COMPARATOR; Interventions: Other: RRT for acute kidney failure using the IHD (intermittent HD) | Intervention Type: OTHER; Name: RRT for acute kidney failure using the CVVH method; Assigned to Arm(s): CVVH arm | Intervention Type: OTHER; Name: RRT for acute kidney failure using the IHD (intermittent HD); Assigned to Arm(s): IHD arm
D: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.


Options:
A: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
B: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
C: Arm Label: Standard Anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Arm Label: Citrasate; Type: EXPERIMENTAL; Interventions: Drug: Citrasate | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): Standard Anticoagulation | Intervention Type: DRUG; Name: Citrasate; Assigned to Arm(s): Citrasate
D: Arm Label: heparin; Type: ACTIVE_COMPARATOR; Interventions: Other: regional anticoagulation with citrate | Arm Label: Citrate; Type: ACTIVE_COMPARATOR; Interventions: Other: HfCitPre | Intervention Type: OTHER; Name: regional anticoagulation with citrate; Assigned to Arm(s): heparin | Intervention Type: OTHER; Name: HfCitPre; Assigned to Arm(s): Citrate

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Randomized study to evaluate the efficacy and safety of nafamostat mesilate use during continuous renal replacement therapy in acute kidney injury patients at a high risk of bleeding.


Options:
A: Arm Label: Nafamostat mesilate group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nafamostat mesilate | Arm Label: No anticoagulation group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Nafamostat mesilate; Assigned to Arm(s): Nafamostat mesilate group | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): No anticoagulation group
B: Arm Label: citrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: trisodium citrate | Arm Label: nadroparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: nadroparin | Intervention Type: DRUG; Name: trisodium citrate; Assigned to Arm(s): citrate | Intervention Type: DRUG; Name: nadroparin; Assigned to Arm(s): nadroparin
C: Arm Label: hemofiltration at 4L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 4 to 2 L/h | Arm Label: hemofiltration at 2L/h; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CVVH 2 to 4L/h | Intervention Type: PROCEDURE; Name: CVVH 4 to 2 L/h; Assigned to Arm(s): hemofiltration at 4L/h | Intervention Type: PROCEDURE; Name: CVVH 2 to 4L/h; Assigned to Arm(s): hemofiltration at 2L/h
D: Arm Label: PR1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Argatroban | Arm Label: PR2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lepirudin | Intervention Type: DRUG; Name: Argatroban; Assigned to Arm(s): PR1 | Intervention Type: DRUG; Name: Lepirudin; Assigned to Arm(s): PR2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Trial on Laparoscopic Subtotal Hysterectomy During Sacral Colpopexy for the Treatment of Severe Pelvic Organ Prolapse (POP) With Bipolar Laparoscopic Loop/Bipolar Morcellator vs Conventional Monopolar Hook/Conventional Morcellator
Brief Summary: This prospective randomized pilot study is aimed to verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.


Options:
A: Arm Label: SORD-BILL; Type: EXPERIMENTAL; Interventions: Procedure: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques | Arm Label: STANDARD; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques | Intervention Type: PROCEDURE; Name: PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques; Assigned to Arm(s): SORD-BILL, STANDARD
B: Arm Label: Single-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-port sacrocolpopexy | Arm Label: Multi-port sacrocolpopexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Multi-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Single-port sacrocolpopexy; Assigned to Arm(s): Single-port sacrocolpopexy | Intervention Type: PROCEDURE; Name: Multi-port sacrocolpopexy; Assigned to Arm(s): Multi-port sacrocolpopexy
C: Arm Label: Hysteropexy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Uphold® LITE | Arm Label: Hysterectomy and USLS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Uterosacral ligament suspension | Intervention Type: PROCEDURE; Name: Uterosacral ligament suspension; Assigned to Arm(s): Hysterectomy and USLS | Intervention Type: PROCEDURE; Name: Uphold® LITE; Assigned to Arm(s): Hysteropexy
D: Arm Label: Enrollment video arm; Type: EXPERIMENTAL; Interventions: Behavioral: Enrollment video | Arm Label: No video intervention arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ULS; Type: EXPERIMENTAL; Interventions: Procedure: ULS | Arm Label: SSLF; Type: EXPERIMENTAL; Interventions: Procedure: SSLF | Arm Label: PMT; Type: EXPERIMENTAL; Interventions: Behavioral: PMT | Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Enrollment video; Assigned to Arm(s): Enrollment video arm | Intervention Type: PROCEDURE; Name: SSLF; Assigned to Arm(s): SSLF | Intervention Type: PROCEDURE; Name: ULS; Assigned to Arm(s): ULS | Intervention Type: BEHAVIORAL; Name: PMT; Assigned to Arm(s): PMT | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease
Brief Summary: Major barriers to controlling cardiovascular diseases (CVDs) in India and elsewhere are: low detection rates, inadequate use of evidence based interventions and low adherence with these interventions. Primary health care is the appropriate setting for improving the prevention and management of these chronic conditions. The investigators will develop and evaluate an innovative mobile health (mHealth) software application -'m-WELLCARE'- which provides a patient health profile, decision support for clinical care, monitoring and feedback for use in Indian Community Health Centers (CHCs). The investigators will conduct this research following the steps proposed by the medical research council (MRC) for evaluation of complex interventions. Technical development of m-WELLCARE will be conducted, user acceptability appraised and potential barriers overcome. m-WELLCARE will be evaluated in CHCs of two states, Haryana and Karnataka. The use made of m-WELLCARE, its impact on patterns of health care received and changes in risk factors achieved will be evaluated.


Options:
A: Arm Label: Advancing Adolescents; Type: EXPERIMENTAL; Interventions: Behavioral: Advancing Adolescents | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Advancing Adolescents; Assigned to Arm(s): Advancing Adolescents
B: Arm Label: Intervention (UCT+HE+PS); Type: EXPERIMENTAL; Interventions: Other: Psychosocial stimulation (PS) | Arm Label: Government Intervention (UCT+HE); Type: SHAM_COMPARATOR; Interventions: Other: Government Intervention (UCT+HE) | Arm Label: Comparison; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Psychosocial stimulation (PS); Assigned to Arm(s): Intervention (UCT+HE+PS) | Intervention Type: OTHER; Name: Government Intervention (UCT+HE); Assigned to Arm(s): Government Intervention (UCT+HE)
C: Arm Label: Soccer League (SL); Type: EXPERIMENTAL; Interventions: Behavioral: Soccer League (SL) | Arm Label: Soccer League/Vocational Training (SL-V); Type: EXPERIMENTAL; Interventions: Behavioral: Soccer League/Vocational Training (SL-V) | Arm Label: Control Condition (CC); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Soccer League (SL); Assigned to Arm(s): Soccer League (SL) | Intervention Type: BEHAVIORAL; Name: Soccer League/Vocational Training (SL-V); Assigned to Arm(s): Soccer League/Vocational Training (SL-V)
D: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease
Brief Summary: Major barriers to controlling cardiovascular diseases (CVDs) in India and elsewhere are: low detection rates, inadequate use of evidence based interventions and low adherence with these interventions. Primary health care is the appropriate setting for improving the prevention and management of these chronic conditions. The investigators will develop and evaluate an innovative mobile health (mHealth) software application -'m-WELLCARE'- which provides a patient health profile, decision support for clinical care, monitoring and feedback for use in Indian Community Health Centers (CHCs). The investigators will conduct this research following the steps proposed by the medical research council (MRC) for evaluation of complex interventions. Technical development of m-WELLCARE will be conducted, user acceptability appraised and potential barriers overcome. m-WELLCARE will be evaluated in CHCs of two states, Haryana and Karnataka. The use made of m-WELLCARE, its impact on patterns of health care received and changes in risk factors achieved will be evaluated.


Options:
A: Arm Label: A - coded unit ID; Type: EXPERIMENTAL; Interventions: Other: clinical decision support | Arm Label: B - coded unit ID; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: clinical decision support; Assigned to Arm(s): A - coded unit ID
B: Arm Label: Facilitated Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Other: Facilitated Clinical Decision Support | Arm Label: Clinical Decision Support Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Clinical Decision Support Only | Intervention Type: OTHER; Name: Facilitated Clinical Decision Support; Assigned to Arm(s): Facilitated Clinical Decision Support | Intervention Type: OTHER; Name: Clinical Decision Support Only; Assigned to Arm(s): Clinical Decision Support Only
C: Arm Label: iCPR randomized providers; Type: EXPERIMENTAL; Interventions: Other: Integrated Clinical Prediction Rule (iCPR) | Arm Label: Control providers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated Clinical Prediction Rule (iCPR); Assigned to Arm(s): iCPR randomized providers
D: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease
Brief Summary: Major barriers to controlling cardiovascular diseases (CVDs) in India and elsewhere are: low detection rates, inadequate use of evidence based interventions and low adherence with these interventions. Primary health care is the appropriate setting for improving the prevention and management of these chronic conditions. The investigators will develop and evaluate an innovative mobile health (mHealth) software application -'m-WELLCARE'- which provides a patient health profile, decision support for clinical care, monitoring and feedback for use in Indian Community Health Centers (CHCs). The investigators will conduct this research following the steps proposed by the medical research council (MRC) for evaluation of complex interventions. Technical development of m-WELLCARE will be conducted, user acceptability appraised and potential barriers overcome. m-WELLCARE will be evaluated in CHCs of two states, Haryana and Karnataka. The use made of m-WELLCARE, its impact on patterns of health care received and changes in risk factors achieved will be evaluated.


Options:
A: Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP control | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Intervention Type: DRUG; Name: Intensive BP control; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control
B: Arm Label: mWELLCARE software arm; Type: EXPERIMENTAL; Interventions: Other: mWELLCARE | Arm Label: Usual care arm; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: mWELLCARE; Assigned to Arm(s): mWELLCARE software arm | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care arm
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Generic Nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Arm Label: Optimized nudge plus AI Chat Bot; Type: EXPERIMENTAL; Interventions: Behavioral: Nudge | Intervention Type: BEHAVIORAL; Name: Nudge; Assigned to Arm(s): Generic Nudge, Optimized nudge, Optimized nudge plus AI Chat Bot
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS reminders of medicines intake | Intervention Type: BEHAVIORAL; Name: SMS reminders of medicines intake; Assigned to Arm(s): Intervention

Answer: B